

10th Euro Global Summit and Expo on

Vaccines & Vaccination

June 16-18, 2016 Rome, Italy



Hosting Organization: Conference Series LLC

2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA Ph: +1-702-508-5200 Ext: 8047, Toll free: +1-800-216-6499
e-mail: eurovaccines@insightconferences.com; eurovaccines@conferenceseries.net

07:30-08:45 Registrations

Appia

conferenceseries.com 08:45-09:00

Opening Ceremony

Keynote Forum

09:00-09:05 Introduction

09:05-09:35 Development of the full length single chain gp120-CD4 (FLSC), a novel vaccine for HIV prevention
Timothy R Fouts, Profectus Biosciences Inc., USA

09:35-10:05 Vaccines moving beyond the next frontier
Rene Labatut, Sanofi Pasteur, France

Networking & Refreshments Break 10:05-10:25 @ Foyer area

10:25-10:55 VGX-3100 drives regression of HPV16/18 CIN2/3 and robust cellular immune responses in blood and cervical tissue in a blinded, randomized, placebo-controlled phase 2b study
Prakash Bhuyan, Inovio Pharmaceuticals, USA

Group Photo

Track 1: Cancer Vaccines

Track 2: Vaccine Products and Delivery Technologies

Track 3: Vaccine Research and Development

Track 4: Vaccines for Respiratory Infections

Track 5: HIV Vaccines

Track 6: Veterinary vaccines

Session Chair: Timothy R Fouts, Profectus Biosciences Inc., USA

Session Co-chair: Qingsheng Li, University of Nebraska-Lincoln, USA

Session Introduction

10:55-11:15 Pre-clinical evaluation of the therapeutic application of a vaccine targeting the 12 protease cleavage sites
Ma Luo, University of Manitoba, Canada

11:15-11:35 Distinct transcriptome profiles of Gag-specific CD8+ T cells temporally correlated with the protection elicited by live attenuated SIV
Qingsheng Li, University of Nebraska-Lincoln, USA

11:35-11:55 TAT, the forgotten target that could help to cure from HIV
Erwann P Loret, ETRAV Laboratory, France

11:55-12:15 Community engagement during the Ebola vaccine trial in Guinea
Godwin Enwere, World Health Organization, Switzerland

12:15-12:35 Pre-clinical toxicology considerations in vaccine
Nabil Al-Humadi, Food and Drug Administration, USA

Lunch Break 12:35-13:25 @ Restaurant

13:25-13:45 Codon harmonization, a step beyond optimization to capture the natural rhythm of protein translation
Bettina Werle, Bioaster, France

13:45-14:05 Development of lipid based oral vaccine formulations
Sarah Margaret Hook, University of Otago, New Zealand

14:05-14:25 Viral vectored genetic vaccines: Current status and future perspectives
Antonella Folgori, Reithera SRL, Italy

14:25-14:45 Active immunization against proprotein convertase subtilisin/kexin type 9 (PCSK9): A new strategy to control hyperlipidemia
Gunther Staffler, AFFiRiS AG, Austria

14:45-15:05 Development of a production and purification platform for virus like particles (VLP) vaccine candidates: A case study
Anissa Boumlic-Courtade, Merck Life Science, France

15:05-15:25 MATS: Global coverage estimates for 4CMenB, a novel multi-component meningococcal B vaccine
Duccio Medini, GSK Vaccines, Italy

Networking & Refreshments Break 15:25-15:45 @ Foyer area

15:45-16:05 Implementing a randomized control trial (RCT) in the context of an Ebola epidemic
Godwin Enwere, World Health Organization, Switzerland

16:05-16:25 Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge
Peter Burkhard, Alpha-O Peptides AG, Switzerland

- 16:25-16:45 **Plant expression platforms for vaccine production**
Kathleen Hefferon, Cornell University, USA
- 16:45-17:05 **What do Lebanese women know about cervical cancer and human papillomavirus prevention? A report on awareness levels in urban communities**
Jacques Choucair, Saint Joseph University, Lebanon

Young Researchers Forum

- 17:05-17:20 **Isolation and characteristics identification of bovine rotaviruses from vaccinated dairy calves in Morocco**
Ennima Imane, University Mohammed V of Rabat, Morocco
- 17:20-17:35 **Bluetongue virus (BTV) serological survey and evidence of emergent BTV-8 serotype in Morocco**
Kamar Drif, Institut Agronomique et Veterinaire Hassan II, Morocco
- 17:35-17:50 **Evaluation of the protection conferred by an attenuated vaccine (Mass-type H120) of avian infectious bronchitis against a new emerging Italy 02 genotype in Moroccan broiler chickens**
Khadija Khataby, University Hassan II of Casablanca, Morocco

Panel Discussion

Day 2 June 17, 2016

Appia

Keynote Forum

- 09:00-09:30 **Towards affordable conjugate vaccines: Efficient chemistry and low cost carrier protein**
Andrew Lees, Fina Biosolutions LLC, USA
- 09:30-10:00 **Human vaccines and vaccination for non-infectious diseases**
Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy
- Networking & Refreshments Break 10:00-10:20 @ Foyer area
- 10:20-10:50 **Challenges and dilemmas about vaccines against the herpesviruses : The case of EBV**
Emmanuel Drouet, Université Grenoble-Alpes, France

Track 7: Vaccines against Infectious diseases

Track 8: Viral Vaccines

Track 9: Bacterial Vaccines

Track 10: Childhood Vaccines

Track 11: Hepatitis Vaccines

Track 12: Toxoid Vaccines

Session Chairs: Giulio Filippo Tarro, Foundation T. & L. de Beaumont Bonelli for Cancer Research, Italy

Andrew Lees, Fina Biosolutions LLC, USA

Session Introduction

- 10:50-11:10 **Rapid development of an oral Zika virus vaccine**
Sean N Tucker, Vaxart Inc., USA
- 11:10-11:30 **Preclinical development of HeV-sG as a vaccine and m102.4 as a post exposure prophylaxis against henipavirus infections**
Timothy R Fouts, Profectus Bio-Sciences, USA
- 11:30-11:50 **Measles: Need for continued vaccination and novel vaccines post virus eradication**
S Louise Cosby, Agri-Food and Biosciences Institute, UK
- 11:50-12:10 **Evaluation of genetic stability of transgenes in vaccine**
Ali Azizi, Sanofi Pasteur, Canada
- 12:10-12:30 **Process development for pneumococcal protein vaccines based on recombinant pneumococcal surface protein A (PspA) and hybrids of PspA and pneumolysin toxoid**
Viviane Maimoni Goncalves, Instituto Butantan, Brazil

Lunch Break 12:30-13:20 @ Restaurant

- 13:20-13:40 **The key person influences flu vaccination among health workers: Perspective study of social network**
Xiaoning Hao, China National Health Development Research Center, China
- 13:40-14:00 **Pneumococcal conjugate vaccine: Use of pneumococcal surface protein A (PspA) as carrier**
Giovana Cappio Barazzone, Instituto Butantan, Brazil
- 14:00-14:20 **Construction and immunological study on recombinant multi-epitope adenovirus vaccine for influenza virus**
Hui-jun Lu, Changchun Veterinary Institute of CAAS, China
- 14:20-14:40 **Pneumococcal inactivated whole cell vaccine: Development of the production process**
Viviane Maimoni Goncalves, Instituto Butantan, Brazil
- 14:40-15:00 **Knowledge, attitude and practices and influencing factors related to seasonal influenza vaccination among healthcare workers in Qingdao, China, 2013-14: A prospective cohort study**
Xiaoning Hao, China National Health Development Research Center, China
- 15:00-15:20 **Polio outbreak review in the Middle East and polio immunization mop-up campaigns in the Lebanese/Syrian refugees' context and post campaign results**
Randa Hamadeh, Ministry of Public Health, Lebanon

Networking & Refreshments Break 15:20-15:40 @ Foyer area

- 15:40-16:00 **Prevalence of tuberculin negativity after BCG vaccination in the under five Saudi children and the need for revaccination**
Fahad Saleh Al-Tayyeb, King Abdulaziz Medical City, KSA
- 16:00-16:20 **Vaccination of hepatitis B in healthy adults: Effect of sex and age, two protocols of revaccination in non-responders**
Jacques Choucair, Saint Joseph University, Lebanon

Panel Discussion

Breakout

Cassia Meeting Room

Workshop on

Revisiting HIV inactivation, elite controllers, immunogenetics and HIV therapeutic vaccines

Session Chairs: Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain

- 09:00-09:30 **Expanding the findings of RV144 to South Africa: P5 initiative**
Glenda Gray, South African Medical Research Council, South Africa
- 09:30-10:00 **Therapeutic vaccination with Tat restores immune homeostasis, promotes proviral DNA decay and induces cross-clade neutralizing antibodies in patients on HAART: Results from phase II clinical trials in Italy and South Africa**
Barbara Ensoli, National AIDS Center-Istituto Superiore di Sanità, Italy

Networking & Refreshments Break 10:00-10:20 @ Foyer area

- 10:20-10:50 **Current strategies for HIV remission: The role of therapeutic vaccines**
Felipe Garcia Alcaide, Hospital Clinic de Barcelona, Spain
- 10:50-11:20 **Synthetic DNA vaccines for difficult mucosal viruses including HIV**
Jean D. Boyer, Inovio Pharmaceuticals Inc., USA
- 11:20-11:50 **Potential development of inactivated HIV-1 transmitted/founder virus (T/F) vaccine**
Adan Rios, PhotImmune Biotechnology Inc., USA

11:50-12:20 Discussion

Lunch Break 12:20-13:20 @ Restaurant

Session Chairs: Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France

Eric Sandstrom, Karolinska Institutet, Sweden

- 13:20-13:50 **HIV vaccine development: Is a moral wrong occurring?**
Mike King, University of Otago, New Zealand
- 13:50-14:20 **Reverse HIV vaccinology failed because it has no sound theoretical basis in the case of this virus**
Marc H.V. Van Regenmortel, Biotechnology School of the University of Strasbourg, France
- 14:20-14:50 **HIV replication is suppressed by CD8+T- regulatory cells in elite controllers**
Jean Marie Andrieu, Paris-Descartes University, France
- 14:50-15:20 **Concerns in the planning of therapeutic immunizations in HIV infected patients aiming to harness HLA E restricted CD8+T-cell HIV suppressive activity**
Eric Sandstrom, Karolinska Institutet, Sweden

Networking & Refreshments Break 15:20-15:40 @ Foyer area

- 15:40-16:10 **Multiple immunogenetic aspects in susceptibility to HIV-1 infection progression toward AIDS and rational vaccine design**
Massimo Amicosante, University of Rome, Italy

Workshop Discussion

Poster Presentations 16:10-17:00

- EVACC 01 **Role of insulin like growth factor-1 derived from macrophages in an influenza vaccine induced humoral immune response**
Jae-Hwan Nam, Catholic University of Korea, South Korea
- EVACC 02 **Visualization of immune response to hepatitis B vaccination by in vivo small animal imaging**
Hyewon Youn, Seoul National University, South Korea
- EVACC 03 **Development immunogen for protection against PRRSV infection using Korean isolates ORF5 protein expression using baculovirus expression system**
Sun Shin Yi, Soonchunhyang University, South Korea
- EVACC 04 **Vaccine potentials of excretory-secretory antigens of 4 week old juveniles against Fasciola gigantica in mice**
Narin Changklungmoa, Burapha University, Thailand
- EVACC 05 **Vaccine potentials of recombinant mature cathepsin L1H against Fasciola gigantica in mice**
Pornanan Kueakhai, Burapha University, Thailand
- EVACC 06 **Characterization and vaccination of the cytosolic Fasciola gigantica superoxide dismutase**
Wipaphorn Jaikua, Mahidol University, Thailand
- EVACC 07 **Study for manufacture and establishment of 1st national standard material for cell derived Japanese encephalitis vaccine (Beijing strain)**
Ji Young Hong, National Institute of Food and Drug Safety Evaluation, Korea

- EVACC 08 **Histone deacetylase 10 (HDAC 10) deacetylates Foxp3 and modulates its stability**
Suna Gu, Chonbuk National University, Republic of Korea
- EVACC 09 **In silico design of epitope based peptide vaccine against virulent strains of HN-Newcastle disease virus (NDV) in poultry species**
Marwa Mohamed Osman, Africa City of Technology, Sudan

Day 3 June 18, 2016

Appia

Track 13: DNA Vaccines
Track 14: Vaccine Safety and Efficacy
Track 15: Vaccine Adjuvants
Track 16: Tuberculosis Vaccines
Track 17: Vaccination for Pregnant Women
Track 18: Human Preventive and Therapeutic Vaccines

Session Chair: Emmanuel Drouet, Université Grenoble-Alpes, France

Session Co-Chair: Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Session Introduction

- 10:00-10:20 **Vaccines for pregnant women - challenges and opportunities for harmonized safety monitoring**
Sonali Kochhar, Global Healthcare Consulting, India
- 10:20-10:40 **Exploiting a high dose murine challenge model for HSV to identify potential DNA prime subunit boost vaccine strategies that could be translated to human clinical trials**
Timothy R Fouts, Profectus Biosciences Inc., USA

Networking & Refreshments Break 10:40-11:00 @ Foyer area

- 11:00-11:20 **Operational experience and lessons learned on influenza vaccination post authorization safety studies**
Ombretta Palucci, Quintiles, Switzerland
- 11:20-11:40 **Post-marketing surveillance of BCG vaccination**
Ruwen Jou, Tuberculosis Research Center at Centers for Disease Control, Taiwan
- 11:40-12:00 **Novel vaccine adjuvants for animal infectious diseases**
Jishu Shi, Kansas State University, USA
- 12:00-12:20 **Emerging market challenges: Development of a thermostable and immunologically active solid HPV vaccine formulation**
Ramesh Chintala, Merck & Co. Inc., USA

Lunch Break 12:20-13:10 @ Restaurant

- 13:10-13:30 **Immunogenicity of VLP forming baculoviral DNA vaccine**
Young Bong Kim, Konkuk University, Republic of Korea
- 13:30-13:50 **Targeting TLR9 and TLR21 to develop vaccine adjuvant for different species**
Tsung-Hsien Chuang, National Health Research Institutes, Taiwan
- 13:50-14:10 **Therapeutic vaccines for treatment of allergic and autoimmune diseases**
Zhikang Peng, University of Manitoba, Canada
- 14:10-14:30 **Therapeutic vaccines against chronic hepatitis-B virus and related complications**
Sheikh Mohammad Fazle Akbar, Toshiba General Hospital, Japan

Panel Discussion & Closing Ceremony

Bookmark your dates

19th Euro Global Summit and Expo on

Vaccines & Vaccination

June 19-21, 2017 Paris, France

e-mail: eurovaccines@insightconferences.com; eurovaccines@vaccineconferences.com
Website: vaccines.global-summit.com/europe

Conference Series LLC
2360 Corporate Circle, Suite 400
Henderson, NV 89074-7722, USA
Ph: +1-888-843-8169
Fax: +1-650-618-1417
america@conferenceseries.com

Conference Series Ltd.
Traian Str., No.61, Constanta 900720,
Romania, Tel: 0805-080048
Heathrow Stockley Park Lakeside
House, 1 Furzegrund Way, Heathrow,
UB11 1BD, United Kingdom
europe@conferenceseries.com

OMICS International
6th Floor, North Block, Divyasree
Building, Raidurg Hyderabad,
Telangana, INDIA-500032
Tel: +91-40-33432300
asia.pacific@conferenceseries.com

Toll free
USA & Canada: +1-800-216-6499
Australia: +1-800-651-097
Europe: 0805-080048